The addition of nab-paclitaxel to gemcitabine and cisplatin did not improve survival in advanced biliary tract cancer.

February is National Cancer Awareness Month, a time to amplify discussions on lesser- known but equally devastating ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

We measured circulating HBV RNA (cirB-RNA) in untreated and nucleos(t)ide analogues (NUC) treated chronic hepatitis B (CHB) patients to define its correlation with intrahepatic viral markers and HBV ...

These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) ...

fusions in patients with intrahepatic cholangiocarcinoma, with the first demonstration of anti-tumor activity with FGFR inhibitors in this patient population. Subsequent work led to the FDA ...

Expression of Trop2, Nectin-4, and FOLR1 cell surface markers in biliary tract cancers: Is it time to repurpose drugs? This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies.

fusions in patients with intrahepatic cholangiocarcinoma, with the first demonstration of anti-tumor activity with FGFR inhibitors in this patient population. Subsequent work led to the FDA approval ...

Hepatocellular carcinoma is the most common form of liver cancer. It can begin as a single tumor or multiple small tumors throughout the liver. Intrahepatic Cholangiocarcinoma A cancerous tumor in the ...

题为“A Novel 167-Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination”，本研究阐明了环状 PCSK6-167aa 对 NF-κB ...